Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials
Executive Summary
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
The latest drug development news and highlights from our FDA Performance Tracker. Vaxchora cholera vaccine is CBER's fourth novel biologic cleared this year; Adamis emergency Epi turned down again.
Novartis And The Medicines Company: Five Things To Worry About
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: